Wall Street Turns Bullish on Geron Corporation (GERN) amid Rytelo Sales Push Plans

Photo by National Cancer Institute connected Unsplash

The institution plans to displacement Rytelo’s usage to earlier attraction lines. Part of the program entails positioning the campaigner cause for earlier usage successful the attraction setting, particularly arsenic a second-line therapy. Geron is to instrumentality a surround-sound attack that volition summation doc consciousness and engagement. While the drug’s income stagnated successful 2025 astatine astir $50 million, the institution is optimistic of important maturation successful 2026.

Amid the projected income plans for Rytelo, Needham expert Gil Blum has reiterated a Buy standing and acceptable a $4 terms target. On the different hand, Leerink Partners reiterated an Outperform standing connected the banal connected November 5 but chopped the terms people to $2 from $3. Leerink reaffirmed an outperform rating, expecting the institution to instrumentality the indispensable steps to amended Rytelo’s performance, including expanding its tract force.

Geron Corporation (NASDAQ:GERN) is simply a biopharmaceutical institution focused connected processing and commercializing medicines to dainty humor cancers, specifically myeloid hematologic malignancies. Its main product, RYTELO (imetelstat), is an approved telomerase inhibitor for definite patients with lower-risk myelodysplastic syndromes, and the institution is researching its usage successful different humor cancers.

While we admit the imaginable of GERN arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: Top 10 Stocks Offering High Upside Potential successful Data Centers and 10 Best Breakout Stocks to Invest In.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.